gmp
gmp

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: GHIT Fund

            Deal Size: $0.8 million Upfront Cash: Undisclosed

            Deal Type: Funding September 29, 2020

            Details:

            Funds will be used for Cry5B optimization for Trichuris - whipworm which is beign conducted by Kao Corporation, PATH, University of Massachusetts Medical School.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: GHIT Fund

            Deal Size: $0.07 million Upfront Cash: Undisclosed

            Deal Type: Funding September 29, 2020

            Details:

            Funds will be used for screening project between Daiichi Sankyo RD Novare and DNDi for hit identification of a Chagas disease, Leishmaniasis Drug.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 14, 2020

            Details:

            Company has initiated a new R&D program to identify novel compounds that block the activity of the SARS-CoV-2 MPro protease (Nsp5), which has been designated as potential target for drug development.